Anna Ivanova is a journalist who writes for Renewables Now Ltd, with her work also appearing in PR.com. She specializes in reporting on the renewable energy sector, including articles on solar installations, wind energy projects, hydrogen initiatives, and clean energy developments in various countries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Anna's coverage predominantly focuses on energy-related topics, particularly renewable energy such as solar and wind power. This suggests that she would likely be interested in receiving pitches related to new developments and innovations within the renewable energy sector, including government announcements, industry breakthroughs, or major private sector initiatives.
Given Anna’s focus on press releases and government/private sector announcements, she may be receptive to pitches containing exclusive details about upcoming projects in the renewable energy space or insights from key figures involved in these sectors. Additionally, given her interest in business & industry themes as well as a seemingly unrelated fashion article listed among her titles, there is potential for broader business-focused stories if they have an innovative angle tied to her areas of focus.
This information evolves through artificial intelligence and human feedback. Improve this profile .
free articles left this month Get 5 more for free Sign up for Basic subscription
free articles left this month Get 5 more for free Sign up for Basic subscription
Saudi Arabia has launched the qualification process for the first group of battery energy storage system (BESS) projects with a total capacity of 2,000 MW/ 8,000 MWh as part of its efforts to expand renewable energy in its power mix.
free articles left this month Get 5 more for free Sign up for Basic subscription
free articles left this month Get 5 more for free Sign up for Basic subscription
By: Anna Ivanova
The Herder Institute for Historical Research on East Central Europe, the University of Birmingham, and the Martin-Opitz-Library are pleased to announce
free articles left this month Get 5 more for free Sign up for Basic subscription
German gas network operator Thyssengas GmbH has launched work on the development of hydrogen pipelines, set to form part of the nation's
UAE-based companies, in collaboration with Chinese and Egyptian partners, plan to develop gigawatt-scale solar energy and battery storage projects, alongside manufacturing solar equipment and battery technology in Egypt, as part of a broader energy partnership between the two Arab nations.
By: Anna Ivanova, Eva Wolf, Celia Jonson-Oldenbuettel, Sebastian Noe, Celia A. Jonsson-Oldenbuettel, Carmen Wiese, Ariane E. Von Krosigk, Farhad Schabaz
BackgroundVirologic failure (VF) is still a major concern in the use of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) for many healthcare professionals (HCP). While many results from clinical trials have been published, there is suspicion that they might underestimate the risk under less-controlled real-life conditions.This study aimed to estimate the probability of VF (primary objective) as well as discontinuation for any reason (secondary objective) among people with HIV (PWH) on CAB and RPV LA every two months (Q2M) in real life using Bayesian methodology.MethodsBayesian estimation of VF based on prior knowledge about VF and discontinuation on CAB and RPV Q2M from randomized controlled trials (ATLAS-2M, SOLAR) and real-world data from CAB and RPV LA from a large single-center cohort.ResultsAmong 175 PWH, two (1.1%) met the criteria of VF through week 48 (W48), resulting in an estimated risk of VF at W48 of 1.2% [0.6%; 1.9%] using Bayesian estimation. In one of the PWH, two-class resistance was observed at the time of VF, most likely being therapy emerging.The probability of discontinuation for any reason by W48 was 21.4%, leading to a Bayesian risk estimate of 8.9% [7.3%; 10.5%]. The main reasons for discontinuation were injection-site reactions (n=10).ConclusionsRisk of VF on CAB and RPV LA under real-life conditions seems to be comparable to results in clinical trials. This finding can be reassuring for both PWH and HCPs considering CAB and RPV LA as an alternative to oral antiretroviral treatment, particularly when considering the risk factors for VF that have been identified from the cases of VF in the clinical trials for patient selection.At the same time, rates of discontinuation may be considerably higher. However, this does not seem to be an indicator of a worse safety profile outside clinical trials, but probably could be the result of making CAB and RPV LA available to a wider population of PWH.
(833) 317-6278 
